Clinical analysis of 20 patients with angioimmunoblastic T-cell lymphoma
10.3760/cma.j.issn.1009-9921.2012.01.012
- VernacularTitle:血管免疫母细胞性T细胞淋巴瘤20例临床分析
- Author:
Zhi GUO
;
Xuepeng HE
;
Kai YANG
;
Xiaodong LIU
;
Peng CHEN
;
Bing LIU
;
Dan LIU
;
Bingran WANG
;
Huiren CHEN
- Publication Type:Journal Article
- Keywords:
Immunoblastic lymphadenopathy;
Treatment outcome;
Disease-free survival
- From:
Journal of Leukemia & Lymphoma
2012;21(1):42-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective To improve the diagnosis efficiency of patients with angioimmunoblastic T-cell lymphoma (AILT)by analyzing the clinical characteristics and curative effect of AILT. Methods Retrospective studies were used on clinicopathological features,immunophenotypes,treatment and survival of 20 angioimmunoblastic T-cell lymphoma patients,who were collected between January 2005 and January 2010 of Beijing Military General Hospital. Results In the 20 patients receiving chemotherapy,the median age was 55.9 years old.All of the 20 had lymph nodes and 11 of whom were accompanied with B group of symptoms,which were confirmed by lymph node biopsy and T cell antigen CD3, CD45Ro positive expression in all the patients. ALL of the patients received the CHOP regimen and combining with other treatment such as DICE,ESHAP, Hyper-CVAD or autologous hematopoietic stem cell transplantation. A follow-up by 5 to 69 months showed that median survival was 20.2 (5-69) months and 1,2,and 3-year disease free survival (DFS) were 67 ％,33 ％,and 11％ respectively.8 patients of the group (40 ％) with a sustained remission (CCS) respectively survived 63,47,27,24,24,12,5,1 months so far.Conclusion Most patients were older with many complications during chemotherapy, which resulted in easy relapse, and even the symptoms were alleviated at the early stage of the chemotherapy. IPI prognostic index is more important with long-term survival in AITL.Therefore further studies are required to improve the outcome.
